Leading While Diverse

Diversity Research Institute

The National Diversity Council is proud to present “Leading While Diverse,” a comprehensive research report ranking top pharmaceutical companies based on the diversity of their C-Suite and Board of Directors. Purchase today to see how your company compares to the rest of industry and learn more about the business case for diversity in leadership.

Check out the Report Preview (PDF)

 

Companies Surveyed

Abbvie
Actavis/Allergan
Amgen
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-MyersSquibb
Daiichi Sankyo
EliLilly(500)
Gilead Sciences
GSK GlaxoSmithKline
Johnson-Johnson
Merck KGaA
Merck
Novartis
Novo Nordisk
Otsuka (OAPI – American)
Pfizer (500)
Roche
Sanofi
Takeda
TevaPharmaceuticalIndustries

Executive Summary

The pharmaceutical industry is undergoing critical structural changes led by the high rate of patent expiration. This report makes the case for greater diversity within corporate governance—executive leaders and board members—within the pharmaceutical industry. Specifically, it examines the current literature on corporate governance and the business case for diversity with respect to current structural trends occurring across the pharmaceutical industry. It concludes with a case for diverse corporate governance.

To do so, this report assesses the current diversity of corporate governance within the top-performing 25 pharmaceutical companies. These companies were identified through the Pharmaceutical Executive Report, which ranked them according to overall 2014 sales. Then, using a Census-based biographical approach, we conducted an analysis of diversity within corporate governance, measuring the board members and executive officers that identify as people of color and/or as women per company. We have developed the Diversity and Inclusion Ranking to establish a benchmark by which to measure corporate governance diversity, and to examine a company’s progress yearly.

We reveal three major findings: The first is that there is a strong correlation between financial performance of pharmaceutical companies and the recognition they have received for their diversity programs and their CEO commitment. The second finding is that diversity measured in terms of gender is greater than diversity measured in terms of race and ethnicity. This has led us to maintain two company rankings with regards to gender (GDIR) and with regards to race and ethnicity (PDIR). The last finding is that the top-performing pharmaceutical companies did not prove to be competitive in the area of corporate governance diversity. While white male constituents across corporate diversity are as high as 70%, women of color constituents are as low as 2%.

Thus, this report contends that multinational pharmaceutical companies necessitate diverse corporate governance, in order to lead in innovative strategic thinking, meet customer demands for social responsibility, and build distinguished patient care that sets them apart from emergent industry competition.

What’s Included

Rankings
Companies are ranked based on how inclusive their leadership is with regards to:

  • Women
  • People of Color
Data Breakdown
The report provides a comprehensive breakdown of the selected companies’ leadership according to the following criteria:

  • White Women
  • Women of Color
  • People of Color
  • White Men

Latest Trends and Best Practices

The report outlines global pharmaceutical trends aligned with diversity and inclusion business strategies and presents a business case for a diverse C-Suite and Board of Directors.

Purchase today to:

  • Monitor diversity and inclusion rankings year to year
  • See how diversity in corporate leadership helps maximize your bottom line
  • Maintain a competitive edge
  • Enhance your brand

For more information or to purchase, please contact Lucy Carrillo at lucy.carrillo@nationaldiversitycouncil.org